A detailed history of Royal Bank Of Canada transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 24,130 shares of CRDL stock, worth $30,886. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,130
Previous 27,105 10.98%
Holding current value
$30,886
Previous $54,000 12.96%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.83 - $2.48 $5,444 - $7,378
-2,975 Reduced 10.98%
24,130 $47,000
Q2 2024

Aug 14, 2024

BUY
$1.67 - $2.97 $17,828 - $31,707
10,676 Added 64.98%
27,105 $54,000
Q1 2024

Nov 05, 2024

SELL
$0.88 - $2.06 $9,394 - $21,992
-10,676 Reduced 39.39%
16,429 $29,000
Q1 2024

May 15, 2024

SELL
$0.88 - $2.06 $15,556 - $36,416
-17,678 Reduced 51.83%
16,429 $29,000
Q4 2023

Feb 14, 2024

SELL
$0.67 - $1.0 $6,929 - $10,342
-10,342 Reduced 23.27%
34,107 $28,000
Q3 2023

Nov 14, 2023

BUY
$0.76 - $1.19 $4,353 - $6,816
5,728 Added 14.79%
44,449 $40,000
Q2 2023

Aug 14, 2023

SELL
$0.45 - $0.97 $6,257 - $13,487
-13,905 Reduced 26.42%
38,721 $34,000
Q1 2023

May 15, 2023

BUY
$0.47 - $0.81 $12,443 - $21,444
26,475 Added 101.24%
52,626 $25,000
Q4 2022

Feb 14, 2023

SELL
$0.48 - $1.0 $1,578 - $3,288
-3,288 Reduced 11.17%
26,151 $13,000
Q3 2022

Nov 14, 2022

BUY
$1.02 - $1.41 $6,247 - $8,636
6,125 Added 26.27%
29,439 $30,000
Q2 2022

Aug 15, 2022

SELL
$1.03 - $2.05 $12,257 - $24,394
-11,900 Reduced 33.79%
23,314 $31,000
Q1 2022

May 16, 2022

BUY
$1.25 - $2.31 $17,525 - $32,386
14,020 Added 66.15%
35,214 $54,000
Q4 2021

Feb 14, 2022

BUY
$1.83 - $4.86 $12,808 - $34,015
6,999 Added 49.31%
21,194 $39,000
Q3 2021

Nov 15, 2021

BUY
$2.03 - $4.8 $28,815 - $68,136
14,195 New
14,195 $59,000

Others Institutions Holding CRDL

About Cardiol Therapeutics Inc.


  • Ticker CRDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 61,942,500
  • Market Cap $79.3M
  • Description
  • Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...
More about CRDL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.